Published in Aging and Elder Health Week, June 18th, 2006
The novel oral formulation provides rapid absorption of apomorphine directly into the bloodstream after sublingual (under the tongue) administration. This novel formulation would offer patients an improved alternative to the currently available injectable formulation of apomorphine.
Rick Stewart, CEO of Amarin, commented on the new acquisition, "This oral formulation of apomorphine potentially represents an important breakthrough for the treatment of Parkinson...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.